Suggestions
Eric H. Hanson MD, MPH
Everything MILMED, MedTech, BioPharma, and Federal non-dilutive funding | Physician | Advisor | Researcher | Veteran | CEO@MILMED Connect, a Techstars portfolio company | CEO@Tier Seven
Professional Background
Eric H. Hanson, MD, MPH, is a distinguished leader in the realm of military medicine and biotechnology, bringing over two decades of experience in navigating the complexities of non-dilutive funding for research and development (R&D). As the CEO of MILMED Connect, a Techstars portfolio company, Eric specializes in supporting MedTech and BioPharma companies in innovating their dual-use technologies and accessing substantial funding opportunities available through the Department of Defense (DoD) and federal resources.
With an impressive track record of securing over $300 million in non-dilutive funding, Eric is passionate about sharing his expertise to help organizations efficiently capture funding without enduring the lengthy learning curves that can accompany such endeavors. His role as a consultant, advisor, and strategist has solidified him as a trusted partner in the field, offering insights that are grounded in integrity and transparency.
Eric's extensive career encompasses pivotal positions within both military and civilian sectors, providing him with a unique perspective on the intersection of military medicine and civilian commercialization requirements. His commitment to fostering innovation and impactful partnerships in the biomedical landscape is evident, as he navigates the pathways that lead to successful market entry for emerging technologies.
Education and Achievements
Eric H. Hanson holds an MD in Medicine from the Uniformed Services University and a Master of Public Health (MPH) degree, specializing in Epidemiology with a concentration in Genetics, from The Johns Hopkins University. His foundational education also includes a Bachelor’s degree in Pre-Medicine from Oregon State University. This impressive educational background combines both medical and public health perspectives, equipping Eric with the knowledge and skills to contribute significantly to the healthcare industry.
In addition to his academic accomplishments, Eric has published 25 peer-reviewed articles, authored five books, and is a proud holder of nine patents. His endeavors in academic and scientific writing reflect his dedication to advancing knowledge within the medical community. As an educator, Eric has trained over 50 military medical advisors, many of whom have gone on to establish their own companies, further enhancing the ecosystem of innovation in military medicine.
Professional Accomplishments and Roles
Throughout his career, Eric has excelled in various leadership and advisory roles, significantly impacting organizations across the biomedical field. He formerly served as the Chief Executive Officer at MILMED Connect, where he led the organization in its mission to support the advancement of dual-use technologies. His role as the USU Military Medical Ambassador at the Uniformed Services University of the Health Sciences exemplifies his dedication to bridging military medicine with broader civilian health initiatives.
Eric's work has not only focused on direct advisory services; he has also been pivotal in establishing Collaborative Research and Development Agreements (CRADAs) between the industry and DoD principal investigators at no cost to industry. Over the past 12 years, he has facilitated more than three dozen CRADAs, demonstrating his commitment to fostering collaboration and innovation in the healthcare sector.
His previous positions include Chief, Operational Biotechnology and Genomics at the Epidemic Outbreak Surveillance (EOS) program and Division Chief of Science and Technology at the US Air Force Medical Service. These roles have empowered Eric to apply his scientific expertise to real-world challenges in both military and health sectors, ensuring his ability to effectively guide organizations in securing vital funding and support.
Networking and Community Involvement
Eric is also known for his proactive approach in connecting individuals within the military medicine community. He encourages participation in the MILMED Community, which promotes access to training, resources, templates, and case studies for MILMED professionals. This initiative not only equips participants with the tools needed to succeed in the biomedical field but also fosters a spirit of collaboration and shared learning among peers.
As an Accredited Investor at the Keiretsu Forum and an advisory board volunteer at the OTRADI Bioscience Incubator, Eric has the experience and network to guide emerging biotech ventures through their funding processes, positioning them well for future success.
Conclusion
In summary, Eric H. Hanson, MD, MPH, stands as a notable figure in the military and civilian biomedical landscape. His profound expertise in strategic funding pathways, combined with a wealth of experience in military medicine, uniquely positions him to assist MedTech and BioPharma companies seeking to innovate and navigate the complexities of federal funding opportunities. Through his leadership at MILMED Connect and contributions to the broader community, Eric continues to inspire and facilitate impactful advancements in health technology. For those looking to tap into the vast opportunities available within military medicine and government funding, connecting with Eric could prove to be a transformative experience.
tags':['Funding Expert','MedTech Innovation','BioPharma Advisor','Non-Dilutive Funding','Biomedical R&D','Military Medicine','Health Technology','Government Contracts','Medical Device Funding','R&D Strategy','Clinical Medicine Specialist','Health Partnerships','Public Health Specialist','Epidemiology','CRADA Expert','Peer-Reviewed Research','Veteran Leadership'],
questions
How can Eric H. Hanson leverage his military experience to enhance MedTech funding strategies?
What unique strategies does Eric H. Hanson propose for capturing $25B in DoD and $26B in annual biomedical R&D funding?
How does Eric H. Hanson approach the intersection of military medicine and civilian commercialization?
What lessons has Eric H. Hanson learned from advising over 20 companies in the MedTech and BioPharma sectors?
In what ways can emerging medical technologies benefit from Eric H. Hanson's expertise in non-dilutive funding applications?
